Oncotarget

Research Papers:

Lentinan dose dependence between immunoprophylaxis and promotion of the murine liver cancer

Ying Wang, Xue Han _, Yan Dong Li, Yabing Wang, Shi Yang Zhao, Dong Jie Zhang and Yu Lu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:95152-95162. https://doi.org/10.18632/oncotarget.19808

Metrics: HTML 1462 views  |   ?  


Abstract

Ying Wang1,4, Xue Han2, Yan Dong Li3, Yabing Wang2, Shi Yang Zhao2, Dong Jie Zhang1 and Yu Lu5

1College of Food, Heilongjiang Bayi Agricultural University, Daqing 163319, PR China

2College of Biological Science and Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, PR China

3Hebei Institute of Veterinary Drugs Control, Shijiazhuang 050000, PR China

4National Coarse Cereals Engineering Research Center, Daqing 163319, PR China

5Huabei Petroleum Administration Bureau, Huasheng Integrated Service, Tianjin 300000, PR China

Correspondence to:

Xue Han, email: hanxue_h@163.com

Keywords: lentinan; dose dependence; liver cancer; immunoprophylaxis; promotion

Received: March 12, 2017    Accepted: April 21, 2017    Published: August 01, 2017

ABSTRACT

Lentinan could exhibit significant biological activity favorable for human health and disease control such as the recovery of patients with liver cancer. In order to investigate the effect of lentinan dose dependence between immunoprophylaxis and promotion of cancer cell proliferation of the murine liver cancer, different concentrations of lentinan were prepared for the test in vitro (MTT assay) and in vivo (cumulative survival assay, spleen lymphocyte proliferation tests and peritoneal macrophage phagocytosis assays). New emerging proteins of the H22 cell incubated with lentinan was demonstrated by MS analysis and protein database searching. Lentinan was non-toxic for HL7702 cells but inhibited H22 cells proliferation obviously in a dose-dependent manner. In vivo, the proliferation of H22 hepatocarcinoma cells was inhibited by lentinan 0.4mg/kg body weight (L2, survival rate, 20%, P<0.01 vs model); while it was promoted in L3 group (lentinan 1mg/kg body weight) on the contrary. The stimulation index of L2 group (SI-ConA, 8.1; SI-LPS, 6.37) showed a significant improvement compared to that of model group (P<0.01). But for the mice L3 group (SI-ConA, 1.8; SI-LPS, 1.7) was remarkably depressed compared to that of control group (P<0.01). Six proteins 60Sacidic ribosomal protein P2, Peroxiredoxin-2, Annexin A5, PDZ and LIM domain protein 1, Src substrate cortactin and Moesin were found as emerging proteins of the H22 cell incubated with high dose lentinan which related to cancer promotion closely. In conclusion, Thelentinan was relatively safe and could inhibit the proliferation of H22 cancer cells through immunity improvement when it’s intake was in proper quantity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19808